When do biologic drug patents expire and when will biosimilars launch?

United States Patent 10,596,141: Claims and U.S. Patent Landscape for Chemotherapy-Induced Thrombocytopenia Treatment Using a “Formula 2” Compound

Executive summary: U.S. Patent 10,596,141 is positioned around a method of treating chemotherapy-induced thrombocytopenia (CIT) by administering a Formula 2 compound that maintains platelet thresholds (not below 25,000/µL and/or 50,000/µL, and optionally not more than a 70% decrease). Claim scope expands via (i) formulation constraints (substantially free of other monoacetyl diacyl glycerol and/or triglycerides), (ii) administration details (notably soft gelatin capsules with specific dose ranges and tocopherol antioxidants), (iii) explicit chemotherapeutic agent lists and disease settings, and (iv) mechanism-linked biomarkers (complement C3 suppression; STAT6 activity reduction). The estate’s enforceability risk is concentrated in whether the Formula 2 compound and its purity/formulation elements are novel over earlier U.S. filings and whether mechanism/bioassay statements are tied to enablement and clear definitions.

What is US Patent 10,596,141 claiming for treating chemotherapy-induced thrombocytopenia (CIT)?

Core claim architecture: The patent is a dependent-method claim set that layers three main claim “axes” onto a single therapeutic foundation:

Patient and clinical outcome constraints
Compound definition and dosing constraints (Formula 2)
Formulation and mechanistic biomarkers constraints

Claim 1: the broadest independent method anchor

Claim 1 covers:

A method for treating myelosuppressive chemotherapy-induced thrombocytopenia by administering to a human in need an effective amount of a compound of Formula 2
With a clinical platelet endpoint limitation: platelet count “does not decrease to less than 25,000/µL”

Interpretive consequences for claim scope

The “Formula 2” compound definition is the dominant novelty hook. The platelet endpoint becomes a functional limitation that may be used to differentiate prior art regimens, but it is also the easiest place for validity and infringement fights (see sections below).
The claim does not require any mechanistic biomarker, specific chemotherapy agent, specific dose, or specific formulation type.

Claims 2 and 3: purity and excipient-free constraints

Claim 2: formulation substantially free of other monoacetyl diacyl glycerol compounds
Claim 3: formulation substantially free of triglyceride compounds

These are unusual claim levers for method patents. They can be powerful in licensing and litigation because they create clear formulation restrictions that third parties can attempt to avoid via formulation selection. They also raise enablement/definiteness and prior-art composition issues if earlier disclosures already described substantially triglyceride-free or substantially monoacetyl diacyl glycerol-restricted compositions.

Claim 4: chemotherapy agent list tied to the method

Claim 4 enumerates a large set of chemotherapy-related agents that can cause CIT, including targeted anti-cancer biologics and cytotoxics (examples: Ziv-aflibercept, Brentuximab vedotin, Pralatrexate, Ganciclovir, Valganciclovir, Romidepsin, Ruxolitinib, Decitabine, Imatinib, Topotecan, Lenalidomide, Irinotecan, anthracyclines, Gemcitabine, Cytoxan, Paclitaxel, and multiple classes by mechanism).

Impact: This claim expands practical coverage by not restricting to a single oncology backbone. It also gives a litigation path for plaintiffs to argue “your regimen is within the enumerated list,” even if your protocol differs clinically.

Claims 5–6: narrower chemo subsets

Claim 5: chemotherapeutic agent selected from cyclophosphamide, doxorubicin, etoposide, ifosfamide, mesna, cisplatin, gemcitabine, tamoxifen and lenalidomide
Claim 6: chemotherapeutic agent is lenalidomide

Impact: Claim 6 provides a strong targeting hook for lenalidomide-driven oncology programs.

Claim 7: disease context

Covers patients with:

multiple myeloma
CML
acute myeloid leukemia
myelodysplastic syndrome

Claims 8–11: optional G-CSF co-therapy

Claim 8: further administering G-CSF
Claim 10: G-CSF selected from filgrastim, pegfilgrastim, lenograstim
Claim 11: G-CSF is filgrastim

Impact: This is a key “combination standard of care” path. If the Formula 2 therapy is used alongside G-CSF (common in practice), the dependent claims support arguments of infringement without requiring monotherapy.

Claims 12 and 22: mechanistic biomarker limitations

Claim 12: the method suppresses upregulated/activated Complement 3 (C3)
Claim 22: STAT6 activity is reduced upon administering the Formula 2 compound

Impact: These add biological plausibility and potentially constrain prior art. But they also raise litigation questions: whether prior art therapies also modulate C3 or STAT6 in ways that would meet the claim; and whether the specification ties these biomarker results to reproducible assays and thresholds.

Claims 13–20: formulation and oral dosage detail (soft gelatin capsule + antioxidant)

Claim 13: solid/liquid/gel/suspension; oral or non-oral
Claim 14: oral administration
Claim 15: soft gelatin capsule containing Formula 2 with a pharmaceutically acceptable diluent/carrier
Claim 16: total daily dosage 250–2000 mg
Claim 17: further comprises pharmaceutically acceptable antioxidant
Claim 18: antioxidant selected from ascorbic acid (E300), tocopherols (E306), propyl gallate (E310), TBHQ, BHA, BHT
Claim 19: soft capsule containing 250–1000 mg Formula 2, substantially free of triglycerides, plus 0.1–3 mg tocopherol
Claim 20: example: about 500 mg Formula 2 + about 1 mg tocopherol once or twice daily

Impact: These are the highest “design-around” points. Competitors can attempt to:

change capsule technology
remove tocopherol
change triglyceride content
shift dose outside the claimed windows
recharacterize “substantially free” compositions

But note: dependent claims still require the base method of Claim 1 plus the formulation constraints. If the formulation is fully changed, those dependent claims may not read.

Claims 21, 23, 24: alternative platelet-outcome windows

Claim 21: platelet count does not decrease more than 70%
Claim 23: total daily dosage 1000–2000 mg
Claim 24: platelet count does not decrease to less than 50,000/µL

Impact: These dependent outcome/dosing claims create multiple infringement “tripwires.” In litigation, plaintiffs often select the outcome provision that best matches available clinical or post-marketing data.

How strong is the patent estate around US 10,596,141’s “Formula 2” compound identity?

Strength driver: The independent method claim rests on the Formula 2 compound (chemical entity identity). The strongest validity outcome for the patentee is typically achieved when:

Formula 2 is not disclosed in prior art with the same structure; and
the prior art does not teach using that compound to prevent CIT with the specific platelet endpoint thresholds; and
earlier monoacetyl diacyl glycerol or lipid-compound disclosures do not anticipate the combined constraints of platelet preservation + specific formulation purity + (for dependent claims) C3/STAT6 effects.

Primary vulnerability: If the “Formula 2” compound is already known in the art (even for other indications), the remaining barriers become “obviousness” of the new therapeutic use and “obviousness” of formulation purity/excipient selection. For lipid-class molecules, generic freedom-to-operate often hinges on whether earlier patents disclose the same compound, or close analogs plus scalable formulation guidance.

What patents or prior art typically challenge claims like these for CIT using lipid-related compounds?

A typical pre-trial and PTAB strategy against method-of-use claims like these is to combine:

Known compound disclosures (structure and synthesis)
Known thrombocytopenia management (including CIT)
Known immunology/inflammation targets (complement C3, STAT6 pathways)
Known formulation constraints (lipid digestion products, monoacyl diacyl glycerol mixtures, triglyceride-free or low-triglyceride compositions, capsule formulations with tocopherols)

Even without enumerating individual patents here, the structure of Claim 10,596,141 shows the likely prior-art categories that matter:

lipid composition patents covering monoacetyl diacyl glycerols
methods using G-CSF in chemo-induced cytopenias (combination standard care)
immunomodulation patents linked to C3 or STAT6
antioxidant formulation patents for oral lipid-based products

Litigation pattern: If a challenger can show an earlier disclosure of Formula 2 or an equivalent composition plus a routine trial showing platelet preservation above the claimed thresholds, then Claim 1 risks invalidity on anticipation or obviousness; dependent “purity” constraints often get defeated if prior art already describes similar compositions as “substantially free.”

Which claim limitations are most important for infringement analysis in the U.S.?

In method-of-use patents, infringement is often fought on what the accused product actually does clinically and what is in the administered composition.

Most consequential infringement limitations

Platelet endpoint limitation (Claim 1): platelet does not decrease below 25,000/µL
Optional platelet alternative endpoints: no more than 70% decrease (Claim 21) and no less than 50,000/µL (Claim 24)
Composition purity: substantially free of other monoacetyl diacyl glycerols (Claim 2) and triglycerides (Claim 3)
Formulation type: soft gelatin capsule (Claim 15)
Antioxidant/tocopherol content: 0.1–3 mg tocopherol; and example dosing (Claims 19–20)
Biomarker modulation: C3 suppression (Claim 12) and STAT6 reduction (Claim 22)
Combination use: concurrent G-CSF (Claims 8–11)

Practical evidence sources

Clinical trial protocols and results using platelet threshold endpoints
Labeling language, real-world evidence, and TDM (if available)
Formulation specs from CMC filings (FDA correspondence, DMFs, drug master files where accessible in litigation discovery)
Assay results for C3 and STAT6 if trials were immunology-focused

When do generic or biosimilar competitors face entry risk for US 10,596,141?

Entry risk is driven by:

the expiration of the underlying composition/use claims (patent term)
any terminal disclaimers
potential continuations and divisional filings
any patent term adjustments
any additional related patents covering the same Formula 2 entity or formulation

However: the exact expiration schedule (filing date, PTE/PB, maintenance status) is not determinable from the claim text alone. Without the patent’s bibliographic data, a precise timeline cannot be produced.

What Orange Book status questions matter for a method patent like this?

Method patents are often tied to a drug product whose approval may be Orange Book-listed. The key questions typically are:

whether US 10,596,141 is listed in the Orange Book for the relevant NDC and dosage form
whether the listing is for “use” claims only, “drug substance,” or “drug product” claims
whether other patents in the same family block ANDA launch

Because the patent text you provided contains no NDC linkage, no Orange Book status mapping is possible here.

What patent litigation and Paragraph IV challenges could attach to these claims?

The claim structure suggests litigation patterns:

Paragraph IV for an ANDA product that uses the same active ingredient and attempts to avoid purity and formulation constraints by changing lipid composition (reduce triglycerides) or changing antioxidant packages (remove tocopherol).
Suit over combination regimens if the accused label includes G-CSF co-administration, and the clinical outcome evidence matches the platelet endpoints.
Contest over biomarker claims: challengers often argue the biomarker limitations are not met or are not tied to the same therapeutic mechanism.

A full litigation map requires docket-level and Orange Book listing data, which is not present in the prompt.

How do the dependent formulation claims create design-around options?

Purity constraints (Claims 2–3)

If a competitor can market a composition that is not “substantially free” of triglycerides or that includes other monoacetyl diacyl glycerol components, those dependent claims narrow sharply.

Design-around levers

change lipid blend ratios to include defined triglyceride levels
use a different source material that introduces additional monoacetyl diacyl glycerol species
formulate outside the “substantially free” boundary using trace but measurable levels

Litigation then pivots on:

how “substantially free” is construed
acceptable assay limits
batch-to-batch consistency and stability

Soft gelatin capsule + tocopherol (Claims 15, 17–20)

If competitors move to:

tablets, capsules of different excipient profiles, or liquid formulations, or
capsule formulations without tocopherols, or
dosing outside the specified windows

then the dependent formulation claims are harder to enforce. Claim 1 may still be asserted if the Formula 2 compound is still administered and the platelet endpoint limitation is met.

How does the biomarker component (C3/STAT6) affect novelty and enforceability?

Claim 12: Complement 3 suppression

If prior art does immunomodulation but not specifically C3 in a clinically meaningful way, challengers may attack the biomarker limitation as:

not disclosed at the claimed “upregulated/activated” state
not measured in an enabling assay
not linked to the platelet outcomes

Claim 22: STAT6 activity reduction

STAT6 sits in inflammatory signaling frameworks. The enforcement risk is:

prior art therapies may reduce STAT6 in immunology studies
biomarker assays may differ, making “activity reduction” disputed

These biomarker limitations can strengthen the patentee’s narrative of mechanism, but they also widen the evidentiary requirements in infringement.

What do Claims 4–7 add commercially and competitively?

The explicit enumeration of chemotherapeutic agents (Claim 4) and disease states (Claim 7) reduces ambiguity about clinical context. It helps plaintiffs argue that clinicians selecting common CIT regimens fall within the claimed method universe.

Commercial implication: this supports licensing and settlement strategies aimed at oncology label users and manufacturers whose marketed protocols align with those agents.

Key Takeaways

U.S. Patent 10,596,141 is built around a Formula 2 compound administered to preserve platelet counts in chemotherapy-induced thrombocytopenia, with Claim 1 anchored to platelets not below 25,000/µL.
The most enforceable dependent claim levers are formulation purity (substantially free of triglycerides and other monoacetyl diacyl glycerols) and soft gelatin capsule + tocopherol dosing constraints.
Mechanism-linked dependent claims (C3 suppression and STAT6 reduction) add specificity but also raise assay-and-evidence burdens in infringement and enablement challenges.
The strongest design-around routes target the composition “substantially free” language and formulation type (soft gelatin capsule and tocopherol inclusion), while leaving Claim 1 as the residual risk if clinical platelet endpoints are met.

FAQs

1) Does US 10,596,141 require C3 suppression or STAT6 reduction to infringe?

No. Those are dependent claims (Claims 12 and 22). Claim 1 does not require biomarkers.

2) Can an ANDA avoid infringement by changing capsule excipients but keeping the same Formula 2 compound?

It may avoid dependent formulation claims (Claims 15, 17–20), but Claim 1 still requires administering the Formula 2 compound and achieving the platelet endpoint limitation.

3) What is the most litigated endpoint for CIT patents like this?

Usually the clinical platelet threshold tied to the claim, here 25,000/µL (Claim 1) and alternative thresholds/decreases in dependent claims.

4) Do G-CSF co-therapy claims broaden infringement exposure?

Yes. Claims 8–11 cover co-administration scenarios, reducing the need to show monotherapy.

5) Is the chemotherapy agent list in Claim 4 exclusive?

The claim language is an “selected from” list; it is used to define covered chemotherapies, and infringement arguments often focus on whether the accused regimen aligns with enumerated agents.

References

U.S. Patent No. 10,596,141. “Method for treating myelosuppressive chemotherapy-induced thrombocytopenia” (claims provided in prompt).

Title:	Methods for treating thrombocytopenia
Abstract:	The disclosure provides methods for treating, controlling or mitigating leukopenia (e.g. neutropenia) and/or thrombocytopenia, for example in the context of cancer chemotherapy, comprising administration of a monoacetyl-diacyl-glycerol compound, as well as compositions useful therefor.
Inventor(s):	Sohn; Ki-Young (Seoul, KR), Kim; Jae Wha (Daejeon, KR)
Assignee:	Enzychem Lifesciences Corporation (Seoul, KR)
Application Number:	14/951,353
Patent Claims:	see list of patent claims
Patent landscape, scope, and claims summary:	United States Patent 10,596,141: Claims and U.S. Patent Landscape for Chemotherapy-Induced Thrombocytopenia Treatment Using a “Formula 2” Compound Executive summary: U.S. Patent 10,596,141 is positioned around a method of treating chemotherapy-induced thrombocytopenia (CIT) by administering a Formula 2 compound that maintains platelet thresholds (not below 25,000/µL and/or 50,000/µL, and optionally not more than a 70% decrease). Claim scope expands via (i) formulation constraints (substantially free of other monoacetyl diacyl glycerol and/or triglycerides), (ii) administration details (notably soft gelatin capsules with specific dose ranges and tocopherol antioxidants), (iii) explicit chemotherapeutic agent lists and disease settings, and (iv) mechanism-linked biomarkers (complement C3 suppression; STAT6 activity reduction). The estate’s enforceability risk is concentrated in whether the Formula 2 compound and its purity/formulation elements are novel over earlier U.S. filings and whether mechanism/bioassay statements are tied to enablement and clear definitions. What is US Patent 10,596,141 claiming for treating chemotherapy-induced thrombocytopenia (CIT)? Core claim architecture: The patent is a dependent-method claim set that layers three main claim “axes” onto a single therapeutic foundation: Patient and clinical outcome constraints Compound definition and dosing constraints (Formula 2) Formulation and mechanistic biomarkers constraints Claim 1: the broadest independent method anchor Claim 1 covers: A method for treating myelosuppressive chemotherapy-induced thrombocytopenia by administering to a human in need an effective amount of a compound of Formula 2 With a clinical platelet endpoint limitation: platelet count “does not decrease to less than 25,000/µL” Interpretive consequences for claim scope The “Formula 2” compound definition is the dominant novelty hook. The platelet endpoint becomes a functional limitation that may be used to differentiate prior art regimens, but it is also the easiest place for validity and infringement fights (see sections below). The claim does not require any mechanistic biomarker, specific chemotherapy agent, specific dose, or specific formulation type. Claims 2 and 3: purity and excipient-free constraints Claim 2: formulation substantially free of other monoacetyl diacyl glycerol compounds Claim 3: formulation substantially free of triglyceride compounds These are unusual claim levers for method patents. They can be powerful in licensing and litigation because they create clear formulation restrictions that third parties can attempt to avoid via formulation selection. They also raise enablement/definiteness and prior-art composition issues if earlier disclosures already described substantially triglyceride-free or substantially monoacetyl diacyl glycerol-restricted compositions. Claim 4: chemotherapy agent list tied to the method Claim 4 enumerates a large set of chemotherapy-related agents that can cause CIT, including targeted anti-cancer biologics and cytotoxics (examples: Ziv-aflibercept, Brentuximab vedotin, Pralatrexate, Ganciclovir, Valganciclovir, Romidepsin, Ruxolitinib, Decitabine, Imatinib, Topotecan, Lenalidomide, Irinotecan, anthracyclines, Gemcitabine, Cytoxan, Paclitaxel, and multiple classes by mechanism). Impact: This claim expands practical coverage by not restricting to a single oncology backbone. It also gives a litigation path for plaintiffs to argue “your regimen is within the enumerated list,” even if your protocol differs clinically. Claims 5–6: narrower chemo subsets Claim 5: chemotherapeutic agent selected from cyclophosphamide, doxorubicin, etoposide, ifosfamide, mesna, cisplatin, gemcitabine, tamoxifen and lenalidomide Claim 6: chemotherapeutic agent is lenalidomide Impact: Claim 6 provides a strong targeting hook for lenalidomide-driven oncology programs. Claim 7: disease context Covers patients with: multiple myeloma CML acute myeloid leukemia myelodysplastic syndrome Claims 8–11: optional G-CSF co-therapy Claim 8: further administering G-CSF Claim 10: G-CSF selected from filgrastim, pegfilgrastim, lenograstim Claim 11: G-CSF is filgrastim Impact: This is a key “combination standard of care” path. If the Formula 2 therapy is used alongside G-CSF (common in practice), the dependent claims support arguments of infringement without requiring monotherapy. Claims 12 and 22: mechanistic biomarker limitations Claim 12: the method suppresses upregulated/activated Complement 3 (C3) Claim 22: STAT6 activity is reduced upon administering the Formula 2 compound Impact: These add biological plausibility and potentially constrain prior art. But they also raise litigation questions: whether prior art therapies also modulate C3 or STAT6 in ways that would meet the claim; and whether the specification ties these biomarker results to reproducible assays and thresholds. Claims 13–20: formulation and oral dosage detail (soft gelatin capsule + antioxidant) Claim 13: solid/liquid/gel/suspension; oral or non-oral Claim 14: oral administration Claim 15: soft gelatin capsule containing Formula 2 with a pharmaceutically acceptable diluent/carrier Claim 16: total daily dosage 250–2000 mg Claim 17: further comprises pharmaceutically acceptable antioxidant Claim 18: antioxidant selected from ascorbic acid (E300), tocopherols (E306), propyl gallate (E310), TBHQ, BHA, BHT Claim 19: soft capsule containing 250–1000 mg Formula 2, substantially free of triglycerides, plus 0.1–3 mg tocopherol Claim 20: example: about 500 mg Formula 2 + about 1 mg tocopherol once or twice daily Impact: These are the highest “design-around” points. Competitors can attempt to: change capsule technology remove tocopherol change triglyceride content shift dose outside the claimed windows recharacterize “substantially free” compositions But note: dependent claims still require the base method of Claim 1 plus the formulation constraints. If the formulation is fully changed, those dependent claims may not read. Claims 21, 23, 24: alternative platelet-outcome windows Claim 21: platelet count does not decrease more than 70% Claim 23: total daily dosage 1000–2000 mg Claim 24: platelet count does not decrease to less than 50,000/µL Impact: These dependent outcome/dosing claims create multiple infringement “tripwires.” In litigation, plaintiffs often select the outcome provision that best matches available clinical or post-marketing data. How strong is the patent estate around US 10,596,141’s “Formula 2” compound identity? Strength driver: The independent method claim rests on the Formula 2 compound (chemical entity identity). The strongest validity outcome for the patentee is typically achieved when: Formula 2 is not disclosed in prior art with the same structure; and the prior art does not teach using that compound to prevent CIT with the specific platelet endpoint thresholds; and earlier monoacetyl diacyl glycerol or lipid-compound disclosures do not anticipate the combined constraints of platelet preservation + specific formulation purity + (for dependent claims) C3/STAT6 effects. Primary vulnerability: If the “Formula 2” compound is already known in the art (even for other indications), the remaining barriers become “obviousness” of the new therapeutic use and “obviousness” of formulation purity/excipient selection. For lipid-class molecules, generic freedom-to-operate often hinges on whether earlier patents disclose the same compound, or close analogs plus scalable formulation guidance. What patents or prior art typically challenge claims like these for CIT using lipid-related compounds? A typical pre-trial and PTAB strategy against method-of-use claims like these is to combine: Known compound disclosures (structure and synthesis) Known thrombocytopenia management (including CIT) Known immunology/inflammation targets (complement C3, STAT6 pathways) Known formulation constraints (lipid digestion products, monoacyl diacyl glycerol mixtures, triglyceride-free or low-triglyceride compositions, capsule formulations with tocopherols) Even without enumerating individual patents here, the structure of Claim 10,596,141 shows the likely prior-art categories that matter: lipid composition patents covering monoacetyl diacyl glycerols methods using G-CSF in chemo-induced cytopenias (combination standard care) immunomodulation patents linked to C3 or STAT6 antioxidant formulation patents for oral lipid-based products Litigation pattern: If a challenger can show an earlier disclosure of Formula 2 or an equivalent composition plus a routine trial showing platelet preservation above the claimed thresholds, then Claim 1 risks invalidity on anticipation or obviousness; dependent “purity” constraints often get defeated if prior art already describes similar compositions as “substantially free.” Which claim limitations are most important for infringement analysis in the U.S.? In method-of-use patents, infringement is often fought on what the accused product actually does clinically and what is in the administered composition. Most consequential infringement limitations Platelet endpoint limitation (Claim 1): platelet does not decrease below 25,000/µL Optional platelet alternative endpoints: no more than 70% decrease (Claim 21) and no less than 50,000/µL (Claim 24) Composition purity: substantially free of other monoacetyl diacyl glycerols (Claim 2) and triglycerides (Claim 3) Formulation type: soft gelatin capsule (Claim 15) Antioxidant/tocopherol content: 0.1–3 mg tocopherol; and example dosing (Claims 19–20) Biomarker modulation: C3 suppression (Claim 12) and STAT6 reduction (Claim 22) Combination use: concurrent G-CSF (Claims 8–11) Practical evidence sources Clinical trial protocols and results using platelet threshold endpoints Labeling language, real-world evidence, and TDM (if available) Formulation specs from CMC filings (FDA correspondence, DMFs, drug master files where accessible in litigation discovery) Assay results for C3 and STAT6 if trials were immunology-focused When do generic or biosimilar competitors face entry risk for US 10,596,141? Entry risk is driven by: the expiration of the underlying composition/use claims (patent term) any terminal disclaimers potential continuations and divisional filings any patent term adjustments any additional related patents covering the same Formula 2 entity or formulation However: the exact expiration schedule (filing date, PTE/PB, maintenance status) is not determinable from the claim text alone. Without the patent’s bibliographic data, a precise timeline cannot be produced. What Orange Book status questions matter for a method patent like this? Method patents are often tied to a drug product whose approval may be Orange Book-listed. The key questions typically are: whether US 10,596,141 is listed in the Orange Book for the relevant NDC and dosage form whether the listing is for “use” claims only, “drug substance,” or “drug product” claims whether other patents in the same family block ANDA launch Because the patent text you provided contains no NDC linkage, no Orange Book status mapping is possible here. What patent litigation and Paragraph IV challenges could attach to these claims? The claim structure suggests litigation patterns: Paragraph IV for an ANDA product that uses the same active ingredient and attempts to avoid purity and formulation constraints by changing lipid composition (reduce triglycerides) or changing antioxidant packages (remove tocopherol). Suit over combination regimens if the accused label includes G-CSF co-administration, and the clinical outcome evidence matches the platelet endpoints. Contest over biomarker claims: challengers often argue the biomarker limitations are not met or are not tied to the same therapeutic mechanism. A full litigation map requires docket-level and Orange Book listing data, which is not present in the prompt. How do the dependent formulation claims create design-around options? Purity constraints (Claims 2–3) If a competitor can market a composition that is not “substantially free” of triglycerides or that includes other monoacetyl diacyl glycerol components, those dependent claims narrow sharply. Design-around levers change lipid blend ratios to include defined triglyceride levels use a different source material that introduces additional monoacetyl diacyl glycerol species formulate outside the “substantially free” boundary using trace but measurable levels Litigation then pivots on: how “substantially free” is construed acceptable assay limits batch-to-batch consistency and stability Soft gelatin capsule + tocopherol (Claims 15, 17–20) If competitors move to: tablets, capsules of different excipient profiles, or liquid formulations, or capsule formulations without tocopherols, or dosing outside the specified windows then the dependent formulation claims are harder to enforce. Claim 1 may still be asserted if the Formula 2 compound is still administered and the platelet endpoint limitation is met. How does the biomarker component (C3/STAT6) affect novelty and enforceability? Claim 12: Complement 3 suppression If prior art does immunomodulation but not specifically C3 in a clinically meaningful way, challengers may attack the biomarker limitation as: not disclosed at the claimed “upregulated/activated” state not measured in an enabling assay not linked to the platelet outcomes Claim 22: STAT6 activity reduction STAT6 sits in inflammatory signaling frameworks. The enforcement risk is: prior art therapies may reduce STAT6 in immunology studies biomarker assays may differ, making “activity reduction” disputed These biomarker limitations can strengthen the patentee’s narrative of mechanism, but they also widen the evidentiary requirements in infringement. What do Claims 4–7 add commercially and competitively? The explicit enumeration of chemotherapeutic agents (Claim 4) and disease states (Claim 7) reduces ambiguity about clinical context. It helps plaintiffs argue that clinicians selecting common CIT regimens fall within the claimed method universe. Commercial implication: this supports licensing and settlement strategies aimed at oncology label users and manufacturers whose marketed protocols align with those agents. Key Takeaways U.S. Patent 10,596,141 is built around a Formula 2 compound administered to preserve platelet counts in chemotherapy-induced thrombocytopenia, with Claim 1 anchored to platelets not below 25,000/µL. The most enforceable dependent claim levers are formulation purity (substantially free of triglycerides and other monoacetyl diacyl glycerols) and soft gelatin capsule + tocopherol dosing constraints. Mechanism-linked dependent claims (C3 suppression and STAT6 reduction) add specificity but also raise assay-and-evidence burdens in infringement and enablement challenges. The strongest design-around routes target the composition “substantially free” language and formulation type (soft gelatin capsule and tocopherol inclusion), while leaving Claim 1 as the residual risk if clinical platelet endpoints are met. FAQs 1) Does US 10,596,141 require C3 suppression or STAT6 reduction to infringe? No. Those are dependent claims (Claims 12 and 22). Claim 1 does not require biomarkers. 2) Can an ANDA avoid infringement by changing capsule excipients but keeping the same Formula 2 compound? It may avoid dependent formulation claims (Claims 15, 17–20), but Claim 1 still requires administering the Formula 2 compound and achieving the platelet endpoint limitation. 3) What is the most litigated endpoint for CIT patents like this? Usually the clinical platelet threshold tied to the claim, here 25,000/µL (Claim 1) and alternative thresholds/decreases in dependent claims. 4) Do G-CSF co-therapy claims broaden infringement exposure? Yes. Claims 8–11 cover co-administration scenarios, reducing the need to show monotherapy. 5) Is the chemotherapy agent list in Claim 4 exclusive? The claim language is an “selected from” list; it is used to define covered chemotherapies, and infringement arguments often focus on whether the accused regimen aligns with enumerated agents. References U.S. Patent No. 10,596,141. “Method for treating myelosuppressive chemotherapy-induced thrombocytopenia” (claims provided in prompt). More… ↓ ⤷ Start Trial

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Amgen Inc.	NEUPOGEN	filgrastim	Injection	103353	February 20, 1991	⤷ Start Trial	2035-11-24
Amgen Inc.	NEUPOGEN	filgrastim	Injection	103353	June 28, 2000	⤷ Start Trial	2035-11-24
Amgen Inc.	NEULASTA	pegfilgrastim	Injection	125031	January 31, 2002	⤷ Start Trial	2035-11-24
Amgen Inc.	NEULASTA ONPRO	pegfilgrastim	Injection	125031	December 23, 2014	⤷ Start Trial	2035-11-24
Regeneron Pharmaceuticals, Inc.	EYLEA	aflibercept	Injection	125387	November 18, 2011	⤷ Start Trial	2035-11-24
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Patent: 10,596,141

Summary for Patent: 10,596,141